This article was originally published in The Tan Sheet
FDA clarifies the comment period regarding behind-the-counter availability of some nonprescription drugs continues through Dec. 17, the agency says in a Nov. 27 Federal Register notice. The docket for comments on the topic will remain open for 30 days following the meeting FDA conducted Nov. 14 to obtain comments on BTC availability, but in its Oct. 4 notice announcing the meeting, the agency incorrectly listed the deadline as Nov. 28....
You may also be interested in...
The FDA has published fresh guidance taking a tougher stance on sponsor reasons for needing more time to respond to complete response letters.
Stada has named Yann Brun to become the group’s new head of global development, portfolio, regulatory and business development, replacing Robert Knerr. The move is the latest in a string of key appointments at Stada as the firm builds on a series of acquisitions and deals.
A letter from more than 60 leading public health and medical ethics experts has been sent to Pfizer's CEO Albert Bourla.